Vista Pharmaceuticals Complete Financial Statements

In FYNone, Vista Pharmaceuticals (VISTAPH) reported revenue ₹9 Cr, net profit ₹-7 Cr and EPS ₹-1.50, with a net profit margin of -45.5% and ROE of -11.1%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see VISTAPH share price.

11 Years of Data
2025 - 2015

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -45.45% 2025 data
EBITDA Margin -36.36% 2025 data
Operating Margin -40.00% 2025 data
Return on Assets -8.33% 2025 data
Return on Equity -11.11% 2025 data

Balance Sheet Ratios

Current Ratio 8.33 2025 data
Debt to Equity 1.33 2025 data
Equity Ratio 75.00% 2025 data
Asset Turnover 0.18 2025 data

VISTAPH Revenue, Net Profit & EBITDA — Year-on-Year Growth

VISTAPH YoY (March 2025 vs Period) — revenue -18.2%, net profit -40.0%, EBITDA -75.0%, expenses +14.3%.

Revenue Growth
-18.2%
Year-over-Year
Net Profit Growth
-40.0%
Year-over-Year
EBITDA Growth
-75.0%
Year-over-Year
Expense Growth
+14.3%
Year-over-Year
Assets Growth
+3.4%
Year-over-Year
Equity Growth
+9.8%
Year-over-Year
Liabilities Growth
+3.4%
Year-over-Year
Operating Cash Flow Growth
-40.0%
Year-over-Year
Investing Cash Flow Growth
+100.0%
Year-over-Year
Financing Cash Flow Growth
+33.3%
Year-over-Year

VISTAPH Income Statement — Revenue, EBITDA & Net Profit

Vista Pharmaceuticals revenue ₹9 Cr, EBITDA ₹-7 Cr, net profit ₹-7 Cr, EPS ₹-1.50 (None) — net profit margin -45.5%. Explore VISTAPH Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 9 11 11 1 1 2 27 34 29 24 15 14
Expenses 16 14 14 5 2 3 28 30 24 21 13 11
EBITDA -7 -4 -3 -4 -1 -2 -1 4 6 3 3 3
Operating Profit Margin % -99.00% -40.00% -32.00% -443.00% -321.00% -137.00% -21.00% 4.00% 18.00% 13.00% 17.00% 20.00%
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1
Interest 1 1 1 1 1 2 2 2 2 1 1 0
Profit Before Tax -8 -5 -5 -6 -3 -4 -4 1 3 1 1 1
Tax 0 -1 -1 0 -2 -2 0 0 1 0 0 0
Net Profit -7 -5 -5 -6 -1 -2 -4 1 2 1 1 1
Earnings Per Share (₹) -1.50 -0.79 -1.03 -1.54 -0.24 -0.54 -1.22 0.31 0.76 0.46 0.31 0.54

VISTAPH Balance Sheet — Assets, Liabilities & Shareholders' Equity

VISTAPH total assets ₹60 Cr, total equity ₹45 Cr, total liabilities ₹60 Cr (2025) — ROE -11.1%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 60 58 56 56 51 51 53 53 42 26 23
Current Assets 25 23 24 24 15 21 23 28 26 16 12
Fixed Assets 19 19 20 19 20 21 21 18 14 10 11
Capital Work in Progress 10 10 9 9 9 9 9 7 2 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0
Other Assets 31 29 27 27 22 22 24 28 26 16 12
LIABILITIES
Total Liabilities 60 58 56 56 51 51 53 53 42 26 23
Current Liabilities 3 3 5 8 9 6 6 6 6 8 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 45 41 37 36 33 30 36 32 17 11 10
Share Capital 12 9 8 7 7 6 6 6 5 5 5
Reserves & Surplus 33 26 23 28 26 24 30 26 11 6 5

VISTAPH Cash Flow Statement — Operating, Investing & Financing

Vista Pharmaceuticals operating cash flow ₹-7 Cr, investing ₹0 Cr, financing ₹8 Cr, net cash flow ₹1 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -7 -5 -2 -1 -7 1 3 -5 3 -3 -4
Investing Activities 0 -1 -1 0 0 -2 -6 -11 -4 0 0
Financing Activities 8 6 3 1 7 0 1 11 6 3 4
Net Cash Flow 1 0 0 0 0 -1 -1 -4 5 0 0